Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.
PARTNERS
ABOUT US
PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.
LATEST NEWS
2H 2025 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences.
Rebounding Life Sciences M&A Signals Strength for Innovation
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem.
Innovations Advanced by M&A: A New Medicine Treating Anemia for Patients with Myelofibrosis
GlaxoSmithKline (GSK)’s 2022 acquisition of Sierra Oncology combined Sierra’s specialization in developing targeting therapies for rare blood cancers with GSK’s global scale, regulatory experience and commercialization capabilities — leading to approval of the only first-line medicine to treat myelofibrosis patients who have anemia.